Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men.
Int J Urol
; 30(7): 600-604, 2023 07.
Article
in En
| MEDLINE
| ID: mdl-37078488
ABSTRACT
OBJECTIVE:
The precise diagnosis of prostate cancer (PC) is crucial to avoid underdiagnosis, overdiagnosis, and overtreatment. We aimed to compare clinically significant PC (csPC) detection between MRI/ultrasound fusion-targeted prostate (TBx) compared to systematic biopsy (SBx) in biopsy-naïve Japanese men.METHODS:
We included patients with suspect PC due to elevated PSA level or abnormal digital rectal examination, or both. csPC was defined as International Society Urological Pathology (ISUP) grade group ≥2 (csPC-A) and ISUP grade group ≥3 (csPC-B).RESULTS:
This study included 143 patients. Overall PC detection was 66.4% for SBx and 67.8% for MRI-TBx. MRI-TBx presented a significantly higher rate of csPC detection (csPC-A 67.1% vs. 58.7%, p = 0.04, and csPC-B 49.6% vs. 39.9%, p < 0.001) and significantly lower detection of non-csPC-A (0.6% vs. 6.7%). Importantly, MRI-TBx missed 4.9% (7/143) of csPC-A and only 0.7% (1/143) of csPC-B. On the other hand, SBx alone missed 13.3% (19/143) of csPC-A and 4.2% (6/143) of csPC-B.CONCLUSION:
MRI-TBx significantly outperformed 12-cores SBx for csPC detection and decreased non-csPC detection in biopsy-naive men. Performing MRI-TBx without SBx would have missed some csPC, supporting that MRI-TBx synergizes with SBx to increase csPC detection.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostate
/
Prostatic Neoplasms
Type of study:
Diagnostic_studies
/
Observational_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Int J Urol
Journal subject:
UROLOGIA
Year:
2023
Document type:
Article
Affiliation country:
Japan
Publication country:
AU
/
AUSTRALIA
/
AUSTRÁLIA